Biomedicine Daily · Wednesday, 30 September 2026
CBA FRONTIER INSIGHTS
AstraZeneca Puts $2 Billion Into Summit, Anchoring Ivonescimab Alliance
AstraZeneca is investing $2 billion in Summit Therapeutics through a direct purchase of about 109,000 preferred shares, taking roughly 12% of Summit's common shares at $18.36 each, a 10% premium. The deal, expected to close within a week pending regulatory clearances, lifts Summit's cash to an estimated $2.5 billion and clears the financial overhang hanging over the company, which retains full rights to the PD-1/VEGF bispecific ivonescimab in its territories. The partners will also launch trials pairing AstraZeneca's anti-CLDN18.2 ADC sonesitatug vedotin with ivonescimab in gastrointestinal cancers, while the FDA decides Summit's NSCLC BLA by November 14. Elsewhere, AbbVie won approval of the Parkinson's drug tavapadon from its $8.7 billion Cerevel deal, pricing it at $58,800 per year.
Clinical readouts and safety
A synthetic lethal drug for microsatellite instability cancers
Inhibition of the Werner syndrome helicase (WRN) enzyme exploits a new synthetic lethal vulnerability in cancers with microsatellite instability, a phase 1 trial shows. The approach offers a new way to target these tumors beyond immune checkpoint inhibition. No efficacy numbers are reported in the material.
UniQure crashes as Huntington’s gene therapy shows less slowing of disease at 4 years
Four-year data on UniQure's Huntington's gene therapy AMT-130 showed a 44% slowing of disease progression on the cUHDRS in 12 high-dose patients, non-significant versus natural history controls and down from the 75% slowing reported at three years; the stock fell as much as 38% to $24.11. Total functional capacity slowing was 61% and significant, and a three-year analysis of all 15 high-dose patients showed 80% slowing on cUHDRS and 67% on TFC, the timepoint anchoring the submitted BLA. Five high-dose patients, 17%, had treatment-related serious CNS inflammation events, all resolved.
Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial
RO7589831, a first-in-class inhibitor of the synthetic lethal target Werner syndrome helicase, showed some partial responses in the dose-escalation stage of a phase 1 trial in patients with microsatellite instability and/or DNA mismatch repair-deficient solid tumors. The maximum tolerated dose was not reached.
Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial
Once-daily oral small-molecule GLP-1 receptor agonist safiglipron reduced HbA1c by up to 1.45% versus placebo over 32 weeks in people with early type 2 diabetes not taking glucose-lowering medication, in the randomized OUTSTAND-1 trial. Body weight effects were modest. It offers an oral option with glycemic efficacy in this population.
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
Roche has stopped developing emugrobart, an anti-myostatin antibody intended to spare lean mass during weight loss, and rights revert to Chugai, which plans to resume development for spinal muscular atrophy and advance it into Phase 3. Roche had been testing the drug in the Phase 2 GYMINDA trial in combination with tirzepatide. The exit removes Roche's myostatin-targeting approach from the obesity field, leaving enicepatide and petrelintide as its main obesity assets.
Roche cans muscle-preserving obesity drug, hands it back to Chugai
Roche has discontinued development of a muscle-building drug and ended a trial testing it in combination with an anti-obesity injectable, returning the experimental medicine to Chugai. The move removes one candidate from the muscle-preserving approach to obesity treatment.
Regulatory and policy
Fresenius Kabi AG - 733107 - 09/22/2026
FDA issued a warning letter to Fresenius Kabi AG CEO Pierluigi Antonelli on September 22, 2026, citing CGMP violations found during an inspection of Fresenius Kabi USA's sterile injectable plant in Melrose Park, Illinois, from January 27 to February 18, 2026. Violations include inadequate investigations of endotoxin test failures tied to adverse events with famotidine for injection, leading to a recall of three batches, and repeated media fill failures on aseptic lines in 2024 and 2025. FDA found the firm's March 11, 2026 response inadequate and warned that failure to correct the violations could bring seizure or injunction.
AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeover
The FDA has approved tavapadon, branded Juvmo, for adults with Parkinson's disease, giving AbbVie a marketed asset from its $8.7 billion Cerevel Therapeutics acquisition. BMO calls Juvmo the first selective D1/D5 receptor agonist available in the U.S., usable with or without levodopa. AbbVie will list it at $4,900 per 30-day supply, or $58,800 per year, and expects U.S. availability next month, targeting a market opportunity the company puts at $5 billion.
Nonprofits' gene therapy for rare immune disease will cost $3.25M
Two nonprofits are launching their gene therapy Waskyra, which won FDA approval at the end of last year, with a list price of $3.25 million. The therapy treats a rare immune disease. Further details of the launch are behind the paywall.
VeganicSKN Limited - 719883 - 02/09/2026
FDA issued Warning Letter 320-26-44 to VeganicSKN Limited, a drug manufacturer in Rocklea, Queensland, Australia, following an inspection from July 15 to 21, 2025, citing significant CGMP violations that render its drug products adulterated. The letter cites an out-of-specification investigation opened on December 4, 2024, after a contract lab reported a failing result on August 28, 2024, with the batch still released and shipped to the U.S. market and the investigation closed on July 11, 2025 without a root cause. FDA found the August 11, 2025 response inadequate and requires a retrospective review of invalidated OOS results plus a CAPA and remediation plan for its testing and supplier-verification systems.
Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat
The FDA approved Ultragenyx's Fayuvi for Sanfilippo syndrome type A, the first-ever treatment for that condition, shortly after approving the company's first gene therapy, Genglycos, for glycogen storage disease type Ia; each approval came with a priority review voucher worth as much as $200 million. The wins follow the Phase 3 Asire trial failure of apazunersen in Angelman syndrome, which cut the stock nearly 50%, and a January failure of setrusumab in osteogenesis imperfecta that erased $1 billion in value. CEO Emil Kakkis says Ultragenyx will implement significant expense reductions while keeping the setrusumab program and awaiting an upcoming Angelman readout.
Curia New York, Inc. - 728790 - 09/18/2026
The FDA issued a warning letter, reference 320-26-127 dated September 18, 2026, to Curia New York, Inc. CEO Philip Macnabb after a January 28 to February 5, 2026 inspection of its API manufacturing facility in Rensselaer, New York, found CGMP deviations. Analysts performed thousands of unexplained HPLC and UPLC trial injections over 30 months using Empower, over 70 in October 2025 alone via TotalChrom, and about 20 percent of Empower trial injections were acquired or altered in "Developer" mode. The FDA found the firm's February 27, 2026 response inadequate and requires a comprehensive independent investigation of all trial injections.
Industry and deals
Summit snags $2B investment from AstraZeneca, clearing financial overhang
AstraZeneca is investing $2 billion in Summit Therapeutics through a direct equity purchase of about 109,000 preferred shares, giving it roughly 12% of Summit's common shares at $18.36 per share, a 10% premium. The deal, expected to close within a week pending regulatory clearances, lifts Summit's cash to an estimated $2.5 billion and leaves it holding full rights to ivonescimab, the PD-1/VEGF bispecific, in its territories. The partners will also start trials pairing AstraZeneca's anti-CLDN18.2 ADC sonesitatug vedotin with ivonescimab in gastrointestinal cancers, while the FDA decides Summit's BLA for the NSCLC drug by Nov. 14.
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
AstraZeneca has invested $2 billion in Summit Therapeutics, according to the headline of a STAT+ report. Separately, Novo Nordisk licensed a once-weekly oral GLP-1/GIP receptor agonist for obesity from Hengrui Pharma, paying $300 million upfront for global rights outside China, with total deal value of $2.6 billion if milestones are met; the drug is ready for Phase 1 development.
bsky.appSignal or noise? > Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #biotech #healthcare #pharma #pharmaceutical
Novo has agreed a deal worth $2.6 billion with Hengrui for a preclinical GLP-1/GIP drug. Hengrui is described as an in-demand partner in the obesity and metabolic space. No further deal terms or timelines are given.
Merck licenses a KRAS G12D inhibitor for $400M upfront
Merck is licensing a KRAS G12D inhibitor from entrepreneur and synthetic chemist Tao Hu for $400 million upfront. Hu previously sold a different KRAS G12D inhibitor to AstraZeneca in 2023. Terms beyond the upfront payment and next steps were not disclosed.
STAT+: Merck discontinues a crucial antibiotic despite concerns over superbug resistance
Merck has stopped supplying Recarbrio in the U.S., a three-drug combination antibiotic injection approved seven years ago for serious infections in adults and children, including hospital- or ventilator-associated pneumonia and complicated urinary tract and stomach infections in patients with limited or no treatment options. The company did not explain the decision and did not disclose Recarbrio sales in its regulatory filings. The FDA had designated the drug a treatment of last resort to mitigate antibiotic resistance, which limited its market potential.
news.google.comNovo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui - Fierce Biotech
STAT+: Beam Therapeutics sues Chinese biotech, VC-backed startup, alleging theft of intellectual property
Beam Therapeutics, the Cambridge, Mass.-based gene-editing company, has sued former scientist Zi Jun "Emma" Wang, alleging she accessed its electronic laboratory notebooks late at night and on weekends and used the information to co-found Shanghai-based YolTech Therapeutics. YolTech, which recently formed a startup called Serapha Bio with VC firms RA Capital and RTW, is named as a defendant along with Serapha. The case unfolds amid rising tensions between US and Chinese biotech companies.
BioNTech to close three sites in Germany after failing to secure a sale
BioNTech will close three manufacturing sites in Germany after months of searching for buyers without securing a sale. The company had been seeking to divest the facilities but could not lock in a deal. No further details on timing or workforce impact were disclosed in the accessible portion of the report.
Research papers
SON-mediated circular RNA suppression promotes PKR signaling and radiation resistance in glioblastoma
The splicing co-factor SON suppresses circular RNA biogenesis in glioblastoma, and its elevation in radiation-resistant GBM is linked to widespread circRNA loss. SON knockdown raised circRNA abundance and attenuated PKR/NFκB signaling, and overexpression of the SON-suppressed circUSP1 and circSUCO reduced PKR activation and selectively decreased clonogenic survival after irradiation in radiation-resistant cells, with little effect on parental cells. The work defines a SON/circRNA/PKR pathway and points to PKR-inhibitory circRNAs as tools to resensitize resistant GBM to radiotherapy.
Defining pathogenic macrophages in the fibrotic niche of human chronic liver disease
A liver single-cell atlas of 77 patients with chronic liver disease resolves monocyte-derived, pro-fibrotic macrophages into 2 subpopulations of TREM2+ scar-associated macrophages. The analysis identifies OLR1 as a candidate therapeutic target for selectively modulating pro-fibrotic macrophage functions and thereby attenuating liver fibrosis.
Genomic correlates of metastatic competence and progression in human melanoma
Metastatic competence in primary cutaneous melanoma is marked by somatic copy-number alterations and chromosomal instability rather than oncogenic point mutations, which were largely shared between primaries and metastases. Sequencing of 247 stage I/II primary melanomas and 60 matched metastases with median followup of 92 months yielded OncoCycle, a six-gene copy-number signature that predicted relapse independently of clinicopathological features. Matched pairs showed progression driven by continued copy-number evolution, with both monoclonal and polyclonal seeding resolved by clonal reconstruction.
BRCA2 loss drives a PKM1-dominant glycolytic state that is selectively lethal to pyruvate kinase activation
BRCA1/2 loss is linked to a PKM1-dominant glycolytic state with elevated pyruvate kinase activity, found across 10,619 TCGA tumors and isogenic BRCA1/2-deficient models. PKM activation with small-molecule activators, including the FDA-approved mitapivat, triggered superoxide accumulation, disrupted PINK1-dependent mitochondrial quality control, induced DNA damage, and selectively killed BRCA2-deficient tumors in vivo while sparing BRCA2-proficient counterparts. The work recasts homologous recombination deficiency as a metabolic state and identifies PKM activation as a candidate therapy for HR-deficient cancers.
Epigenetic progression of pancreatic cancer to aggressive subtypes involves alternate routes of lineage reprogramming in subtype-intermediate progenitor cells
Single-cell ATAC-seq of 33 primary tumors and 7 metastases from 39 PDAC patients, paired with 10 single-cell RNA-seq profiles, maps the cis-regulatory landscape underlying malignant cell state plasticity. GATA6+/KRT17+ co-accessibility marks a classical-basal subtype-intermediate progenitor state (SIP) with limited epigenetic reprogramming and better clinical outcomes. Classical tumors repressing basal accessibility activate neural-like progenitor and tuft lineage enhancers, while basal committed tumors show esophageal transdifferentiation, both with poorer outcomes and distinct immune and stromal phenotypes.
Early-life colonization by enterotoxigenic Bacteroides fragilis remodels gut epithelial stem cell states to drive colorectal cancer susceptibility
Early-life colonization by enterotoxigenic Bacteroides fragilis (ETBF) remodels colonic epithelial stem cell states and drives colorectal cancer susceptibility. Neonatal ETBF exposure expanded Lgr5+ stem cells, enhanced Atoh1+ secretory differentiation, induced distal colon-specific Wnt hyperactivation, and increased precancerous lesions in ApcMin/+ mice. Non-toxigenic B. fragilis colonization in the same window prevented lesion formation, showing developmental context determines protection or predisposition.
Gut microbiota primes stroke severity via the AHR in intestinal dendritic cells
Indole-producing Escherichia coli in the gut worsens ischemic stroke by activating aryl hydrocarbon receptor (AHR) signaling in dendritic cells. Blocking AHR signaling in those dendritic cells increased their migration from the gut to the meninges, expanded meningeal regulatory T cells, and reduced neuroinflammation. The microbiota-AHR axis in dendritic cells is proposed as a therapeutic target for stroke.
medicalxpress.comNew genetic testing guidance could improve patient diagnosis worldwide
RNA splicing tests can be trusted to classify genetic variants when well designed, according to evidence-based recommendations published in Genome Medicine. Reviewing more than 41,000 variants across 5,458 genes, the authors found minigene assays agreed fully or highly with patient RNA testing in 89% of comparable cases, while only one of seven high-throughput datasets met clinical standards. Variants producing 80% or more abnormal RNA strongly indicated a disease-causing effect, and 20% or less argued against one.
Combining interstrand crosslinking agents with histone deacetylase inhibitors against high grade IDH mutant gliomas
The interstrand crosslinking agent KL-50 retains antiproliferative activity against MMR-deficient IDHmut glioma models, where temozolomide GI values rose 2.2- to 30.4-fold, and extends median survival in BT142 orthotopic xenografts from 107.5 to 194 days. KL-50 plus the HDAC inhibitor belinostat shows synergistic cytotoxicity in BT142, 905, and TS603 cultures, with CRISPR screening implicating PKMYT1 as a determinant of sensitivity. The work offers a preclinical route past MMR-associated TMZ resistance.
medicalxpress.comMicroplastics clog liver immune cells, driving fat buildup in mice
Microplastics swallowed by mice clog the lysosomes of Kupffer cells, the liver's macrophages, impairing their ability to engulf pathogens and defective cells. The stressed macrophages produce more apolipoproteins, prompting surrounding liver cells to store more fat. Particles the size of an average bacterium were particularly harmful to the liver, while particles 10 times smaller accumulated in brown adipose tissue and stimulated heat production instead.
SMYD3 protein degraders in HPV-negative head and neck squamous cell carcinoma.
SMYD3 PROTACs, unlike catalytic inhibitors that lack phenotypic efficacy, degrade SMYD3 and curb proliferation and invasion in HPV-negative HNSCC cell lines. The compound IAP-08 degrades SMYD3 with a DC50 of about 177 nM and Dmax of about 90%, forms ternary complexes with XIAP E3 ligase, and shows favorable pharmacokinetics in vivo. Degradation, but not enzymatic inhibition, reprograms cell cycle, EMT and type I IFN response genes, supporting clinical development of IAP-08 in a disease where SMYD3 is overexpressed in about 60% of tumors.
medicalxpress.comA blood-based approach could enable personalized immunotherapy without the need for a tumor biopsy
Cancer neoantigens and neoantigen-specific T cells can be identified from blood alone, using circulating tumor DNA (ctDNA) sequencing of immune-cell analysis, without a tumor biopsy. In six patients with metastatic melanoma, breast, head and neck, or colorectal cancer, ctDNA analysis identified 63.25% to 97.4% of the neoantigens found by standard tumor tissue analysis, plus neoantigens tissue analysis missed. In a separate cohort of 69 patients with metastatic solid tumors, ctDNA was detectable in 32 (46.4%), and in 14 of 17 colorectal cancer patients (82.4%).
The early RNA decay factor ZC3H18 directs first intron splicing
ZC3H18 is the molecular link between the cap-binding complex and first intron splicing, recruiting early splicing factors through interactions that are mutually exclusive with RNA decay factor binding. This mechanism explains how cap-bound nascent transcripts are directed toward productive splicing rather than degradation.
Low-dose doxorubicin drives caveolin-1 depended re-epithelialization of breast cancer cells as a mechanism of cancer plasticity
Prolonged low-dose doxorubicin pushes mesenchymal-like MDA-MB-231 breast cancer cells toward an epithelial-like state, raising Caveolin-1 and E-cadherin protein levels and producing a compact morphology with more cell-cell contacts. The drug also shifted the lipid-anchored GFP-tH probe from the plasma membrane to the cytoplasm and altered autophagy markers, with decreased LC3-I and increased LC3-II, ATG5, and p62, consistent with autophagosome accumulation and impaired autophagic flux. The work links Ras membrane association and autophagy to phenotypic reprogramming under sub-cytotoxic doxorubicin.
Psychedelic protects against chemotherapy-induced nerve damage
Pretreatment with the psychedelic drug psilocybin prevented chemotherapy-induced peripheral neuropathy in preclinical models. The work, reported in Science by Heles and colleagues, links the effect to preservation of mitochondrial trafficking, a mechanism damaged by platinum-based chemotherapy. The finding points to a way to protect against this dose-limiting adverse effect without altering the chemotherapy itself.
Methods and resources
medicalxpress.comLow-cost platform maps gene activity and metabolites in the same tissue sample
OpenFISH, an open imaging-based spatial transcriptomics platform, cuts total costs by about 95% versus leading commercial platforms and reduces wet-lab time to no more than 13 hours on a standard 20× widefield fluorescence microscope. Modified conductive glass slides let transcript detection survive MALDI-MSI laser processing, so gene activity and metabolites can be mapped on the same tissue section. In 5xFAD Alzheimer's mice, the pipeline showed microglia with the strongest changes and elevated cell-type-associated metabolites.
Opinion and commentary
Reproducibility in biomedical research
Nature Medicine has published a review on reproducibility in biomedical research, posted online on 29 September 2026. The review examines current efforts to harmonize reproducibility terminology and implementation, the barriers that persist, and how the research ecosystem is responding, noting that reproducible practices are still not consistently applied despite being foundational to trustworthy science.
In brief
- Risk from toxic metals can persist months after wildfires, Maui study findsstatnews.com
- Study identifies inherited genetic risk factors in childhood leukemiamedicalxpress.com
- Researchers slow neurodegeneration in mice by barring T cells from the brainstatnews.com
- Severe withdrawal cases point to growing medetomidine usemedicalxpress.com
- Promising therapy for fatty liver disease reduces fat, inflammation, and scarring in preclinical modelsmedicalxpress.com
- Anti-cancer molecules show promise in the fight against malariamedicalxpress.com
Also today
14 events that did not make today's daily, one table per category, one row per event. Open a category to expand.
ClinicalZekunda · Adicet Bio shares promising look at CAR · uniQure stock crashes as Huntington’s gene therapy data weaken · Ascletis challenges psoriasis field with pill; Invivyd plans Covid filing4 ▾▴
Trial starts, early and mid-stage data, and results that did not make the daily.
Deals and financingSTAT+ · ai3Bio · AnaCardio · Ortet …8 ▾▴
Licensing, M&A and financing that did not make the daily.
- STAT+Update
- ai3BioUpdate
- AnaCardioUpdate
- OrtetUpdate
- ARCH ← Population HealthUpdate
- SK pharmtecoUpdate
- Scynexis ← BARDAUpdate
- Fresenius Kabi ← Waltz HealtUpdate
Otherifinatamab deruxtecan · Curium Bexlutry2 ▾▴
Everything else with a concrete event that did not make the daily.
- ifinatamab deruxtecanUpdateMerck and Daiichi Sankyo have voluntarily withdrawn their accelerated approval application for the antibody-drug conjugate ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer after platinum-based chemotherapy, after the FDA said the data did not satisfy requirements for the proposed indication. The application rested on a 48.2% confirmed objective response rate from the Phase 2 IDeate-Lung01 study. A Phase 3 trial in ES-SCLC with enrollment nearing completion continues and could support a future filing.FDA
- Curium BexlutryUpdateFDA